WHY IS END-OF-LIFE SPENDING SO HIGH? EVIDENCE FROM CANCER PATIENTS

Dan Zeltzer; Liran Einav; Amy Finkelstein; Tzvi Shir; Salomon M. Stemmer; Ran D. Balicer

doi:10.1162/rest_a_01066

WHY IS END-OF-LIFE SPENDING SO HIGH? EVIDENCE FROM CANCER PATIENTS

Dan Zeltzer, Liran Einav, Amy Finkelstein, Tzvi Shir, Salomon M. Stemmer, Ran D. Balicer

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

We study the sources of high end-of-life spending for cancer patients. Even among patients with similar initial prognoses, spending in the year postdiagnosis is over twice as high for those who die within the year than those who survive. Elevated spending on decedents is predominantly driven by higher inpatient spending, particularly low-intensity admissions. However, most such admissions do not result in death, making it difficult to target spending reductions. Furthermore, end-of-life spending is substantially more elevated for younger patients, compared to older patients with similar prognoses. Results highlight sources of high end-of-life spending without revealing any natural “remedies.”

Original language	English
Pages (from-to)	511-527
Number of pages	17
Journal	Review of Economics and Statistics
Volume	105
Issue number	3
DOIs	https://doi.org/10.1162/rest_a_01066
State	Published - May 2023

Funding

Funders	Funder number
Pinhas Sapir Center for Development
Koret Foundation

Keywords

Abusive
Aggressive. Cyberbul lying
Bengali
Hate: Sped
Low- resource Language
Toxic Comment

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1162/rest_a_01066

Cite this

@article{f2c81cb4a4f142288ed04b52531267b2,

title = "WHY IS END-OF-LIFE SPENDING SO HIGH? EVIDENCE FROM CANCER PATIENTS",

abstract = "We study the sources of high end-of-life spending for cancer patients. Even among patients with similar initial prognoses, spending in the year postdiagnosis is over twice as high for those who die within the year than those who survive. Elevated spending on decedents is predominantly driven by higher inpatient spending, particularly low-intensity admissions. However, most such admissions do not result in death, making it difficult to target spending reductions. Furthermore, end-of-life spending is substantially more elevated for younger patients, compared to older patients with similar prognoses. Results highlight sources of high end-of-life spending without revealing any natural “remedies.”",

keywords = "Abusive, Aggressive. Cyberbul lying, Bengali, Hate: Sped, Low- resource Language, Toxic Comment",

author = "Dan Zeltzer and Liran Einav and Amy Finkelstein and Tzvi Shir and Stemmer, {Salomon M.} and Balicer, {Ran D.}",

note = "Publisher Copyright: {\textcopyright} 2021 The President and Fellows of Harvard College and the Massachusetts Institute of Technology.",

year = "2023",

month = may,

doi = "10.1162/rest_a_01066",

language = "אנגלית",

volume = "105",

pages = "511--527",

journal = "Review of Economics and Statistics",

issn = "0034-6535",

publisher = "MIT Press",

number = "3",

}

TY - JOUR

T1 - WHY IS END-OF-LIFE SPENDING SO HIGH? EVIDENCE FROM CANCER PATIENTS

AU - Zeltzer, Dan

AU - Einav, Liran

AU - Finkelstein, Amy

AU - Shir, Tzvi

AU - Stemmer, Salomon M.

AU - Balicer, Ran D.

PY - 2023/5

Y1 - 2023/5

N2 - We study the sources of high end-of-life spending for cancer patients. Even among patients with similar initial prognoses, spending in the year postdiagnosis is over twice as high for those who die within the year than those who survive. Elevated spending on decedents is predominantly driven by higher inpatient spending, particularly low-intensity admissions. However, most such admissions do not result in death, making it difficult to target spending reductions. Furthermore, end-of-life spending is substantially more elevated for younger patients, compared to older patients with similar prognoses. Results highlight sources of high end-of-life spending without revealing any natural “remedies.”

AB - We study the sources of high end-of-life spending for cancer patients. Even among patients with similar initial prognoses, spending in the year postdiagnosis is over twice as high for those who die within the year than those who survive. Elevated spending on decedents is predominantly driven by higher inpatient spending, particularly low-intensity admissions. However, most such admissions do not result in death, making it difficult to target spending reductions. Furthermore, end-of-life spending is substantially more elevated for younger patients, compared to older patients with similar prognoses. Results highlight sources of high end-of-life spending without revealing any natural “remedies.”

KW - Abusive

KW - Aggressive. Cyberbul lying

KW - Bengali

KW - Hate: Sped

KW - Low- resource Language

KW - Toxic Comment

UR - http://www.scopus.com/inward/record.url?scp=85168536131&partnerID=8YFLogxK

U2 - 10.1162/rest_a_01066

DO - 10.1162/rest_a_01066

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

AN - SCOPUS:85168536131

SN - 0034-6535

VL - 105

SP - 511

EP - 527

JO - Review of Economics and Statistics

JF - Review of Economics and Statistics

IS - 3

ER -

WHY IS END-OF-LIFE SPENDING SO HIGH? EVIDENCE FROM CANCER PATIENTS

Abstract

Funding

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this